Loading search results…

Scholars @ Weill Cornell Medicine

Help & supportPhase 1 prototype

Browse

Scholars8,803 Publications201,993 Funding7,268 Clinical research17

Loading search results…

Browse

Scholars8,803 Publications201,993 Funding7,268 Clinical research17

FiltersClear all

Status

Recruiting5
Enrolling by invitation1
Active, not recruiting6
Completed5

Study type

Interventional17
Observational1

Phase

Not applicable9
Phase 36
Phase 42

Investigator

Samuel Kim3
Evelyn M. Horn2
Manish Ashwin Parikh2
Dmitriy N. Feldman1
Jim W. Cheung1

Department

Medicine16
Cardiothoracic Surgery1

Condition

Cardiovascular Diseases17
Leukemia, Myeloid, Acute50
Prostatic Neoplasms49
Breast Neoplasms41
Heart Failure31

Intervention type

Drug9
Device6
Behavioral1
Biological1
Diagnostic test1

Sponsor type

Industry13
Other academic3
WCM (investigator-initiated)1

Start date

Has results posted2

Interventional×Cardiovascular Diseases×Clear all

Showing 1–17 of 17 studiesSort:

Enrolling by invitationInterventional · Phase 3NCT03683186 ↗
A Phase 3 Open-label Extension (OLE) Study to Evaluate the Long-term Safety and Efficacy of Ralinepag in Subjects With World Health Organization (WHO) Group 1 Pulmonary Arterial Hypertension (PAH)

FiltersClear all

Status

Recruiting5
Enrolling by invitation1
Active, not recruiting6
Completed5

Study type

Interventional17
Observational1

Phase

Not applicable9
Phase 36
Phase 42

Investigator

Samuel Kim3
Evelyn M. Horn2
Manish Ashwin Parikh2
Dmitriy N. Feldman1
Jim W. Cheung1

Department

Medicine16
Cardiothoracic Surgery1

Condition

Cardiovascular Diseases17
Leukemia, Myeloid, Acute50
Prostatic Neoplasms49
Breast Neoplasms41
Heart Failure31

Intervention type

Drug9
Device6
Behavioral1
Biological1
Diagnostic test1

Sponsor type

Industry13
Other academic3
WCM (investigator-initiated)1

Start date

Has results posted2

Interventional×Cardiovascular Diseases×Clear all

Showing 1–17 of 17 studiesSort:

Enrolling by invitationInterventional · Phase 3NCT03683186 ↗
A Phase 3 Open-label Extension (OLE) Study to Evaluate the Long-term Safety and Efficacy of Ralinepag in Subjects With World Health Organization (WHO) Group 1 Pulmonary Arterial Hypertension (PAH)

Show all 13

Show fewer

Louis J Aronne1
Mario Fl Gaudino1
Madeline R. Sterling1
Parag Goyal1
Reema Bhatt1
Robert J. Kim1
Shmuel Chen1
Xuming Dai1

Show all 50

Show fewer

Neoplasms31
Carcinoma, Non-Small-Cell Lung27
Multiple Myeloma27
Colitis, Ulcerative26
Crohn Disease26
Myelodysplastic Syndromes26
Recurrence25
Atrial Fibrillation23
Neoplasm Metastasis23
Obesity23
Parkinson Disease21
COVID-1920
Colorectal Neoplasms18
Depression18
Hematologic Neoplasms17
HIV Infections16
Non-alcoholic Fatty Liver Disease15
Overweight15
Melanoma13
Idiopathic Pulmonary Fibrosis12
Inflammatory Bowel Diseases12
Leukemia, Lymphocytic, Chronic, B-Cell12
Lung Neoplasms12
Lymphoma, Non-Hodgkin12
Primary Myelofibrosis12
Hypertension11
Myeloproliferative Disorders11
Alzheimer Disease10
Coronary Artery Disease10
Hypertension, Pulmonary10
Leukemia, Myelomonocytic, Chronic10
Stroke10
Urinary Bladder Neoplasms10
Cognitive Dysfunction9
Leukemia9
Lung Diseases, Interstitial9
Pulmonary Arterial Hypertension9
Burkitt Lymphoma8
Carcinoma, Renal Cell8
Chronic Pain8
Fibrosis8
Lymphoma, Follicular8
Lymphoma, Large B-Cell, Diffuse8
Adenocarcinoma Of Esophagus7
Anemia7

Procedure

Evelyn M. HornPI

Intervention: Drug: Ralinepag
Dates: Sep 2019 – Dec 2026 (est.)
Sponsor: United Therapeutics

PAHPulmonary HypertensionPulmonary Arterial Hypertension+8 more

Active, not recruitingInterventional · Not applicableNCT04089059 ↗

A Prospective, Multi-Center, Open Label, Single Arm Clinical Trial Evaluating the Safety and Efficacy of the Cordella™ Pulmonary Artery Sensor System in NYHA Class III Heart Failure Patients (PROACTIVE- HF Trial)

Reema BhattPI

Intervention: Device: Cordella™ Pulmonary Artery Sensor System
Dates: Jan 2020 – Apr 2028 (est.)· Results posted
Sponsor: Endotronix, Inc.

Heart Failure NYHA Class III

RecruitingInterventional · Phase 4NCT04262206 ↗

PRagmatic EValuation of evENTs And Benefits of Lipid-lowering in oldEr Adults (PREVENTABLE)

Parag GoyalPI

Intervention: Drug: Atorvastatin 40 Mg Oral Tablet · Drug: Placebo oral tablet
Dates: Sep 2020 – Dec 2026 (est.)
Sponsor: Duke University

Cognitive Impairment, MildDementiaCardiovascular Diseases

Active, not recruitingInterventional · Not applicableNCT04482062 ↗

Edwards EVOQUE Transcatheter Tricuspid Valve Replacement: Pivotal Clinical Investigation of Safety and Clinical Efficacy Using a Novel Device

Shmuel ChenPI

Intervention: Device: Edwards EVOQUE System · Drug: Optimal Medical Therapy
Dates: Apr 2021 – Dec 2025
Sponsor: Edwards Lifesciences Corp.

Tricuspid Valve RegurgitationTricuspid Valve InsufficiencyTricuspid Valve Disease+3 more

Active, not recruitingInterventional · Not applicableNCT05198674 ↗

The SPYRAL AFFIRM Global Clinical Study of Renal Denervation With the Symplicity Spyral Renal Denervation System in Subjects With Uncontrolled Hypertension (SPYRAL AFFIRM)

Dmitriy N. FeldmanPI

Intervention: Device: Renal Denervation (Symplicity Spyral™)
Dates: Oct 2021 – Mar 2026
Sponsor: Medtronic, Inc.

HypertensionVascular DiseasesCardiovascular Diseases+2 more

Active, not recruitingInterventional · Phase 4NCT05284747 ↗

EVOLVE-MI: A Pragmatic Randomized Multicenter Trial of EVOLocumab Administered Very Early to Reduce the Risk of Cardiovascular Events in Patients Hospitalized With Acute Myocardial Infarction

Samuel KimPI

Intervention: Drug: Evolocumab · Drug: Routine Lipid Management
Dates: Oct 2022 – May 2027 (est.)
Sponsor: Amgen, Inc.

Cardiovascular DiseaseMyocardial InfarctionStroke+1 more

Active, not recruitingInterventional · Phase 3NCT05900141 ↗

A Single Arm, Open Label Extension (OLE), Multicenter Study to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230) in Patients With Cardiovascular Disease Who Have Successfully Completed the Apheresis Parent Study.

Samuel KimPI

Intervention: Drug: Pelacarsen
Dates: Sep 2023 – Aug 2028 (est.)
Sponsor: Novartis Pharma AG

Hyperlipoproteinemia (a)

RecruitingInterventional · Not applicableNCT05908331 ↗

MagicTouch Sirolimus-coated Balloon for Treatment of In-Stent Restenosis in Coronary Artery Lesions

Manish Ashwin ParikhPI

Intervention: Device: Sirolimus Drug Coated Balloon · Device: Plan balloon Angioplasty (POBA)
Dates: Apr 2024 – Sep 2025 (est.)
Sponsor: Concept Medical Inc.

In-Stent RestenosisCardiovascular DiseasesCoronary Artery Disease

Active, not recruitingInterventional · Not applicableNCT06096337 ↗

A Prospective Randomized Multicenter Global Study Comparing Pulsed Field Ablation (PFA) Versus Anti-Arrhythmic Drug (AAD) Therapy as a First Line Treatment for Persistent Atrial Fibrillation

Jim W. CheungPI

Intervention: Device: FARAPULSE™ Pulsed Field Ablation (PFA) System · Drug: Anti-Arrhythmic Drug (AAD): Flecainide, Sotalol, Propafenone, Dofetilide, and Dronedarone
Dates: Dec 2023 – Feb 2026
Sponsor: Boston Scientific Corporation

Persistent Atrial Fibrillation

RecruitingInterventional · Not applicableNCT06271590 ↗

The MAGICAL SV Trial - A Prospective, Multicenter, Randomized, Two-Arm, Single-blind Non Inferiority Trial to Evaluate the Safety and Efficacy of the MagicTouch™ Sirolimus-Coated Balloon in the Treatment of Small Vessels in Patients With Coronary Artery Disease.

Manish Ashwin ParikhPI

Intervention: Device: Sirolimus Drug Coated Balloon · Device: Drug eluting stents (DES)
Dates: May 2025 – Nov 2028 (est.)
Sponsor: Concept Medical Inc.

Coronary Artery DiseaseNative Coronary Artery StenosisCardiovascular Diseases

RecruitingInterventional · Not applicableNCT06486636 ↗

Pericardiotomy in Cardiac Surgery Trial

Mario Fl GaudinoPI

Intervention: Procedure: Left Posterior Pericardiotomy
Dates: Oct 2024 – Sep 2027 (est.)
Sponsor: Hamilton Health Sciences Corporation

Atrial FibrillationAtrial FlutterCardiac Events

RecruitingInterventional · Not applicableNCT07067398 ↗

Improving the Cardiovascular Health of Home Health Aides

Madeline R. SterlingPI

Intervention: Behavioral: Peer Coaching Delivered Life's Essential 8 Program
Dates: Sep 2025 – Oct 2026 (est.)
Sponsor: Weill Medical College of Cornell University

CardiovascularCardiovascular (CV) RiskCardiovascular Disease (CVD) Risk Factors+1 more

CompletedInterventional · Phase 3NCT02981407 ↗